Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation

American Journal of Hypertension

Volumn 25, Issue 10, 2012, Pages 1124-1130

  Ota, Hideki ^a   Furuhashi, Masato ^a   Ishimura, Shutaro ^a   Koyama, Masayuki ^a   Okazaki, Yusuke ^a   Mita, Tomohiro ^a   Fuseya, Takahiro ^a   Yamashita, Tomohisa ^a   Tanaka, Marenao ^a   Yoshida, Hideaki ^a   Shimamoto, Kazuaki ^b   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

adipokine; blood pressure; essential hypertension; family history; fatty acid binding protein; hypertension; insulin resistance

Indexed keywords

ANTIHYPERTENSIVE AGENT; FATTY ACID BINDING PROTEIN 4; TRIACYLGLYCEROL;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ESSENTIAL HYPERTENSION; FAMILY HISTORY; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MEAN ARTERIAL PRESSURE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; BLOOD PRESSURE; FAMILY; FATTY ACID-BINDING PROTEINS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; MIDDLE AGED;

EID: 84866410518     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.88     Document Type: Article

References (37)

1. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7:489-503. (Pubitemid 351767117)
2. Furuhashi M, Ishimura S, Ota H, Miura T. Lipid chaperones and metabolic inflammation. Int J Inflam 2011; 2011:642612.
3. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274:1377-1379. (Pubitemid 26391462)
4. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acidbinding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7:699-705. (Pubitemid 32588026)
5. Maeda K, Uysal KT, Makowski L, Görgün CZ, Atsumi G, Parker RA, Brüning J, Hertzel AV, Bernlohr DA, Hotamisligil GS. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes 2003; 52:300-307. (Pubitemid 36173182)
6. Babaev VR, Runner RP, Fan D, Ding L, Zhang Y, Tao H, Erbay E, Görgün CZ, Fazio S, Hotamisligil GS, Linton MF. Macrophage Mal1 deficiency suppresses atherosclerosis in low-density lipoprotein receptor-null mice by activating peroxisome proliferator-activated receptor-?-regulated genes. Arterioscler Thromb Vasc Biol 2011; 31:1283-1290.
7. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005; 1:107-119. (Pubitemid 43960591)
8. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002; 22:1686-1691.
9. Furuhashi M, Fucho R, Görgün CZ, Tuncman G, Cao H, Hotamisligil GS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008; 118:2640-2650. (Pubitemid 351949791)
10. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-853. (Pubitemid 46024991)
11. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52:405-413.
12. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007; 115:1537-1543. (Pubitemid 46648638)
13. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30:2667-2672. (Pubitemid 47547818)
14. Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:1796-1802. (Pubitemid 47207176)
15. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607. (Pubitemid 19004941)
16. Iimura O. Insulin resistance and hypertension in Japanese. Hypertens Res 1996; 19 Suppl 1:S1-S8.
17. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223. (Pubitemid 9249478)
18. Furuhashi M, Tuncman G, Görgün CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447:959-965. (Pubitemid 46975747)
19. Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 2011; 26:408-413.
20. Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, Yoshida H, Shimamoto K, Hotamisligil GS, Miura T. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS ONE 2011; 6:e27356.
21. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16:72-75. (Pubitemid 36078595)
22. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42:76-81. (Pubitemid 36842239)
23. Furuhashi M, Ura N, Higashiura K, Miyazaki Y, Murakami H, Hyakukoku M, Shimamoto K. Low adiponectin level in young normotensive men with a family history of essential hypertension. Hypertens Res 2005; 28:141-146. (Pubitemid 40663065)
24. Burke V, Gracey MP, Beilin LJ, Milligan RA. Family history as a predictor of blood pressure in a longitudinal study of Australian children. J Hypertens 1998; 16:269-276. (Pubitemid 28101754)
25. Nelson MJ, Ragland DR, Syme SL. Longitudinal prediction of adult blood pressure from juvenile blood pressure levels. Am J Epidemiol 1992; 136:633-645.
26. Li R, Alpert BS, Walker SS, Somes GW. Longitudinal relationship of parental hypertension with body mass index, blood pressure, and cardiovascular reactivity in children. J Pediatr 2007; 150:498-502. (Pubitemid 46602334)
27. van den Elzen AP, de Ridder MA, Grobbee DE, Hofman A, Witteman JC, Uiterwaal CS. Families and the natural history of blood pressure. A 27-year followup study. Am J Hypertens 2004; 17:936-940. (Pubitemid 39361666)
28. Wang NY, Young JH, Meoni LA, Ford DE, Erlinger TP, Klag MJ. Blood pressure change and risk of hypertension associated with parental hypertension: the Johns Hopkins Precursors Study. Arch Intern Med 2008; 168:643-648. (Pubitemid 351468399)
29. Goldstein IB, Shapiro D, Weiss RE. How family history and risk factors for hypertension relate to ambulatory blood pressure in healthy adults. J Hypertens 2008; 26:276-283.
30. Hausberg M, Sinkey CA, Mark AL, Hoffman RP, Anderson EA. Sympathetic nerve activity and insulin sensitivity in normotensive offspring of hypertensive parents. Am J Hypertens 1998; 11:1312-1320. (Pubitemid 28541046)
31. Masuo K, Mikami H, Ogihara T, Tuck ML. Familial hypertension, insulin, sympathetic activity, and blood pressure elevation. Hypertension 1998; 32:96-100. (Pubitemid 28324131)
32. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB, Hotamisligil GS. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006; 103:6970-6975.
33. Melki SA, Abumrad NA. Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation. J Lipid Res 1993; 34:1527-1534. (Pubitemid 23264325)
34. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, Kozakewich H, Bischoff J, Cataltepe S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009; 23:3865-3873.
35. Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol 2011; 162:1564-1576.
36. Lee MY, Tse HF, Siu CW, Zhu SG, Man RY, Vanhoutte PM. Genomic changes in regenerated porcine coronary arterial endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27:2443-2449. (Pubitemid 350203962)
37. Aragonès G, Ferré R, Lázaro I, Cabré A, Plana N, Merino J, Heras M, Girona J, Masana L. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis 2010; 213:329-331.